The core therapeutic application of Afonilum (Choline Theophyllinate) is centered on the long-term, supportive management of conditions that restrict normal breathing. The medicine is commonly used to help manage symptoms and may assist in symptomatic prevention in conditions such as asthma, chronic bronchitis, and emphysema, which fall under the umbrella of obstructive lung diseases.

---

Long-Term Symptomatic Support

This medication is generally considered relevant within clinical settings for patients with chronic conditions characterized by periods of heightened symptoms, such as COPD and Bronchial Asthma. It is applied across domains where additional symptomatic support is needed, assisting with functional stability and contributing to easing the overall symptom load over time. The main indications for use include Bronchial Asthma, Chronic Bronchitis, Emphysema, and Reversible Bronchoconstriction.

“This therapy is commonly used to help manage symptoms that become more disruptive during flare-ups and interfere with daily functioning.”

Relief of Respiratory Distress Symptoms

Afonilum is applied in addressing symptom clusters that may become intense or disruptive, particularly those related to physical breathing discomfort. This includes symptoms such as wheezing, shortness of breath, and the uncomfortable feeling of chest tightness. The therapy helps address groups of symptoms that create noticeable physiological strain, supports the patient during difficult episodes by contributing to easing distress.

Quick Fact: Relief for Nocturnal Symptoms The long-acting nature of the therapy is commonly used to help with specific symptomatic phases, particularly those that manifest or intensify at night (e.g., Nocturnal Asthma) or are triggered by physical exertion (exercise-induced bronchospasm). By providing supportive relief when symptoms interfere with routine activities, it may assist in supporting a sense of stability when symptoms are more noticeable.

Regulatory References

1. NIH MedlinePlus Drug Information

Eligibility Map: Who can and cannot use Afonilum — Official Regulatory Information

---

Populations for whom use is allowed (as stated in label):

• Adults with normal organ function [4.4].
• Children (typically 1 year and older, varying by product form) with established therapeutic clearance profiles [4.1, 4.4].

Populations for whom use is not recommended (if applicable):

• Some product labels for Choline Theophyllinate state the medicine is not recommended for children under 10 years of age [3.3].

Populations for whom use is contraindicated:

• Patients with a known Hypersensitivity to Theophylline, Choline Theophyllinate, or other Xanthine Derivatives [4.2].
• Patients with Active Peptic Ulcer Disease or Underlying Seizure Disorders (unless controlled) [3.2, 3.3].
• Patients with Coronary Artery Disease or Symptomatic Cardiac Arrhythmias where cardiac stimulation is a risk [4.5].

Age-related eligibility rules:

• Older Adults (>60 years): Use requires caution due to documented slower clearance, increasing the risk of accumulation [4.4, 4.7].
• Infants (<1 year): Use requires extreme caution and monitoring due to highly variable and slow elimination rates [4.1, 4.4].

Condition-specific eligibility rules:

• Impaired Liver Function: Use is restricted in patients with cirrhosis, acute hepatitis, or cholestasis as clearance is documented to be reduced by 50% or more [4.2, 4.5].
• Impaired Cardiac Function: Use is restricted in patients with congestive heart failure due to reduced clearance [4.1, 4.7].

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Classified as FDA Pregnancy Category C. Use is warranted only if the potential benefit justifies the potential risk to the fetus [3.1, 5.1].
• Lactation: Theophylline is excreted into human milk. Regulatory caution is advised due to the potential for mild toxicities or irritability in the nursing infant [3.1, 5.2].

---

Eligibility Classifications (High-Level)

Eligibility Severity Classification	Eligibility-Context Constraints
Contraindicated	Hypersensitivity, Active Ulcer Disease, Seizure/Cardiac Risk [3.2, 4.2]
Restricted/Caution	Hepatic/Cardiac Dysfunction, Older Age, High Fever, Smoking [4.2, 4.5]
Pregnancy Category C	Use warranted only if benefit outweighs risk [5.3]

---

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use Afonilum primarily by establishing absolute contraindications (such as a xanthine hypersensitivity) and by imposing restrictions or cautions on populations with physiological conditions (like impaired liver function or advanced age) that severely alter the medicine's clearance and increase the documented risk of systemic accumulation. This structure ensures use is limited to populations whose metabolic profiles are compatible with the medicine's documented pharmacokinetics.

Interactions with other medicines and products

Official regulatory information for Afonilum, which acts via its active component Theophylline, establishes a sensitive interaction profile governed primarily by its metabolism. Co-administration of other medicinal products or substances may significantly alter theophylline’s clearance, leading to changes in systemic exposure.

---

Documented Interaction Patterns

1. Pharmacokinetic (PK) Interactions: Altered Clearance

• Increased Theophylline Exposure (Decreased Clearance): Medicines that inhibit the primary metabolic enzyme, CYP1A2, officially reduce theophylline clearance. These include Fluvoxamine, Cimetidine, and macrolide antibiotics like Erythromycin. Certain quinolone antibiotics, such as Ciprofloxacin and Enoxacin, are associated with a severe reduction in clearance, and their co-administration is often restricted or listed as a high-risk combination in regulatory documents.

• Decreased Theophylline Exposure (Increased Clearance): Enzyme-inducing medicines, such as Phenytoin, Carbamazepine, and Rifampicin, officially increase theophylline clearance. This results in decreased plasma concentrations, which may compromise the expected effect.

2. Pharmacodynamic (PD) Interactions

• Theophylline is documented to antagonize the effects of Adenosine and may officially oppose the sedative action of benzodiazepines. Co-administration with the anesthetic Halothane is associated with an increased risk of ventricular arrhythmias.

3. Interactions with Food and Substances

• The herbal product St. John's Wort is officially documented to increase theophylline clearance. A large single dose of alcohol is documented to temporarily decrease theophylline clearance, increasing systemic exposure. Smoking status is officially noted as a factor that can increase clearance.

How Afonilum Works

The mechanism of Afonilum is executed by its active component, Theophylline, which engages in two primary non-selective molecular actions that modulate airway function and physiological processes.

Enzyme Inhibition and Receptor Blockade

One action involves the non-selective inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4 isoforms . This interaction prevents the degradation of the cellular messenger cyclic AMP (cAMP), leading to its increase in smooth muscle cells, which is a key regulator of smooth muscle contractility. The second action involves blocking Adenosine Receptors, counteracting the constricting signal mediated by endogenous adenosine and increasing neuronal excitability in the central respiratory center via CNS stimulation.

Influencing Inflammatory Pathways

Afonilum also influences inflammatory processes by affecting the nuclear enzyme Histone Deacetylase 2 (HDAC2). This concentration-dependent mechanism helps to suppress the genetic transcription of pro-inflammatory mediators within the airways, resulting in the modulation of inflammatory processes and a decrease in the physiological responsiveness of airway smooth muscle to various mediators.

How to Use Afonilum (Official Administration Guidelines)

Afonilum, containing Choline Theophyllinate, is intended exclusively for oral administration as a long-term maintenance treatment. Its proper use is defined by standards that focus heavily on dose individualization and adherence to a strict schedule.

---

Dosing and Scheduling Principles

Administration Component	Official Instruction Summary
Route and Frequency	Oral administration; taken on a once- or twice-daily schedule (e.g., every 12 or 24 hours). Extended-release forms must be taken at the same time each day to maintain steady blood levels.
Dose Determination	Dosage must be highly individualized by a healthcare provider. The final dose is determined through therapeutic drug monitoring to achieve a target serum concentration, generally between 10 to 15 mcg/mL.
Initial/Maximum Dosing	Starting doses for adults are typically 300 to 400 mg of Theophylline equivalent per day, not to exceed a general maximum of 600 mg/day.

---

Administration Specifics and Constraints

• Formulation Integrity: Extended-release tablets and capsules must be swallowed whole and should not be crushed, cut, or chewed. This is essential to ensure the slow, sustained release of the active component as designed.
• Food Relationship: The medication can generally be taken with or without food, but patients should maintain a consistent pattern. Taking some extended-release capsules with a high-fat meal may alter drug absorption.
• Population Adjustments: Dose adjustments are required for certain patient groups. Older adults (>60 years) and those with hepatic impairment generally require reduced maximum doses and slower titration due to decreased clearance.

Research evidence / Overview of studies for Afonilum (Choline Theophyllinate)

---

Evidence for Use in Bronchial Asthma

Research has extensively used Randomized Controlled Trials (RCTs) and Comparative Clinical Trials to study Afonilum's role in the context of conditions characterized by fluctuating or episodic manifestations, such as chronic bronchial asthma. Studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning, using standardized measures like spirometric parameters (for lung function) and detailed symptom scores to track short-term or episodic symptom patterns.

The studies report how symptoms evolved in the observed populations, particularly for daytime and nighttime asthma symptoms. Findings describe patterns observed in the studies related to changes in objective lung function measurements. However, the overall results across the body of evidence are not uniform, and findings were mixed when evaluating specific aspects of symptom patterns. Evidence remains limited regarding long-term effects, as follow-up durations were typically short, and sample sizes were modest in some older trials.

---

Evidence for Use in Chronic Obstructive Airway Diseases

Research describes the evaluation of Afonilum in conditions marked by functional limitations and cycles of stability and flare-ups, such as Chronic Obstructive Pulmonary Disease (COPD). The available research includes Systematic Reviews and Meta-Analyses of RCTs, often involving adults with stable, moderate to severe chronic airways obstruction. Studies monitored outcomes linked to physiological strain, along with outcomes reflecting daily functioning, over observation periods that extended up to a year.

Research highlights changes measured during the study period, including observed changes in spirometric measures of lung volume and flow. Studies also explored outcomes describing episodic changes, such as the total number and rate of COPD exacerbations. Data show patterns related to inconsistent outcomes across different studies, meaning findings were mixed when assessing the impact on exacerbation rates specifically. As this medicine is often evaluated as an adjunct treatment, the evidence base reflects research exploring its combination with other standard therapies.

---

What Remains Uncertain in the Research Landscape

This research provides context but does not offer individual predictions, as certainty remains low for several factors. Evidence quality varies across studies, and findings were mixed regarding the consistency of certain clinical outcomes. Sample sizes were modest in many of the older trials, which limits the reliability of those specific results. There is limited information for long-term outcomes, as follow-up durations were limited overall. These factors highlight what is known — and what is still uncertain — and contribute to the understanding of the existing research gaps.

Key Studies & References

1. Theophylline and Theophyllinates: General Overview and Clinical Use (StatPearls)
2. Global Strategy for Asthma Management and Prevention (GINA 2023 Full Report)

Common questions about Afonilum (FAQ)

---

Q: Is Afonilum the same as other medications used for similar conditions?

Afonilum's active component is Theophylline, which means it belongs to the official class of Xanthine Derivative medicines, a group used for respiratory support. However, Afonilum is chemically specific: it is defined in regulatory documents as Choline Theophyllinate, which is a salt form of Theophylline combined with choline. This unique composition distinguishes it from standard Theophylline forms.

Q: How does Afonilum differ from [Competitor Drug Name]?

Official documents define Afonilum by its active ingredient, Choline Theophyllinate, which is a key distinguishing feature. This specific compound contains Theophylline, combined with Choline, a formulation intended to potentially enhance its stability and absorption compared to other compounds. Differences from other medicines are related to their unique active ingredients and their specific pharmacological classification.

Q: Does the time of day Afonilum is used affect its outcome?

Official administration guidelines state that long-acting forms should be taken at the same time each day. This guideline is provided to help maintain consistent and stable blood concentrations of the active component, which is important for the desired therapeutic effect.

Q: Do all versions of Afonilum (e.g., brand vs. generic) have the same ingredients?

Regulatory documents confirm Afonilum is a single-entity product whose sole active ingredient is Choline Theophyllinate. For any generic version of this medicine to receive approval, it must contain the identical active ingredient in the same quantity as the brand-name product. Furthermore, generics must meet official bioequivalence standards, which is a regulatory requirement demonstrating that they are expected to work in a comparable manner in the body.

Q: What is the evidence regarding Afonilum use in children?

Regulatory guidelines indicate that children (typically over 1 year) are a population for whom this medicine may be used under strict supervision. Official safety notes clarify that children are considered particularly susceptible to the effects of theophylline. Caution is strongly advised for infants due to highly variable elimination rates, and doses are calculated based on weight and age to mitigate risk.

Q: How long after starting Afonilum do people usually notice a change?

According to patient information, immediate-release forms of the medicine may start to have an effect within about 30 minutes after taking it. For long-term conditions, the full benefits for continuous control are typically achieved only after the medicine reaches and maintains a stable concentration in the blood, which takes longer than a single dose.

Q: Is Afonilum considered a new drug or has it been used for a while?

The active substance in Afonilum, Theophylline, is structurally part of a class known as methylxanthines. This component has a long history and has been used in medicine for many decades. Afonilum itself is a specific salt formulation of this compound and is not considered a new molecular entity in clinical practice.

Q: Are there any common foods or drinks that might interact with Afonilum?

Official drug documents include a specific warning regarding certain common substances. They advise that caffeine, which is present in products like coffee, tea, cola, and chocolate, can potentially increase the blood levels of Theophylline. Elevated levels of the medicine may increase the risk of experiencing adverse effects such as restlessness or nausea.

Q: How long does Afonilum stay in the body after the last use?

The time it takes for the body to clear the medicine can vary significantly between people. However, official pharmacokinetic documents report that the mean elimination half-life for Theophylline in normal adults is generally around 7 to 9 hours. The body is typically understood to have fully cleared the medicine after approximately five half-lives have passed.

Q: What is the general understanding of Afonilum's effect on mental clarity?

Official documents classify effects on the central nervous system (CNS) among the documented side effects. These effects include restlessness, tremor, and insomnia, which are generally related to the medicine's stimulant properties. These adverse reactions may influence a person's level of focus or calm.

Q: Are there any required tests before starting Afonilum?

Official regulatory documents do not mandate specific baseline tests prior to the first dose. However, due to the drug's narrow therapeutic window, the label requires therapeutic drug monitoring (TDM). This involves measuring the medicine's concentration in the blood during treatment to guide precise dose adjustments.

Q: Can people taking Afonilum still drive or operate machinery?

Official patient information indicates that, because the medicine can cause side effects like tremor, headache, or restlessness, patients are directed to determine their individual reaction before driving or operating machinery. This is because these side effects may impair performance.

Q: Is Afonilum often stopped abruptly, or is it usually a gradual process?

Clinical discussions suggest that formal dose tapering is typically not required upon discontinuation. Official guidance suggests there is generally no specific rebound effect. However, stopping treatment may result in the return or possible worsening of the underlying respiratory symptoms for which the medicine was being used.

Q: What should be done if a dose of Afonilum is forgotten?

Standard instructions for a missed dose advise taking the dose as soon as it is remembered. However, if the time is very close to the next scheduled dose, the forgotten dose should be skipped entirely, and the regular schedule should be resumed. Official guidance cautions against taking two doses simultaneously.

Q: Are there any known long-term effects associated with Afonilum use?

Official research evidence reviews have noted that overall information regarding the long-term effects of this medicine is limited. However, some clinical literature on theophylline has explored potential concerns related to bone health, specifically concerning changes in calcium metabolism and bone turnover markers over extended periods.

Q: Is Afonilum available over the counter in any countries?

No. The active component, Theophylline, and all products containing it are classified by regulatory bodies, such as the U.S. FDA since 1995, as being prescription-only. This classification requires authorization from a healthcare professional for the medicine to be dispensed.

Q: How do researchers measure the success of Afonilum in clinical trials?

Researchers utilize both objective and patient-reported measures to evaluate outcomes in clinical trials. Success is typically measured using objective spirometric parameters, such as F E V1 (a measure of lung function). They also use patient-reported measures, like tracking the frequency of respiratory events or using validated quality-of-life assessment scores.

Q: Can Afonilum interact with herbal teas or remedies?

Official regulatory drug documents specifically cite the herbal product St. John's Wort as being documented to increase the clearance of Theophylline from the body. Due to the potential for interactions, official guidance recommends that all herbal supplements, teas, or remedies be discussed with a healthcare provider.

Q: Is Afonilum a common treatment choice, or is it typically reserved for certain cases?

Official context describes theophylline as a medicine for long-term control of chronic respiratory diseases. Clinical consensus, reflected in official documents, suggests it is not typically considered a first-line treatment but is often used as an adjunct (additional) therapy when symptoms are not adequately controlled by other standard medications.

Q: What is the maximum duration of use mentioned in clinical studies for Afonilum?

Reviews of the research evidence indicate that follow-up periods in older trials were often short. However, studies evaluating the medicine's use in Chronic Obstructive Airway Diseases have had observation periods that were documented to extend up to a year. No absolute maximum duration of use is defined in the provided regulatory context.

Q: What is the general understanding of Afonilum's impact on mood?

Official regulatory documents list adverse reactions that are associated with the central nervous system (CNS) stimulant effects of the medicine. These include documented feelings of restlessness and insomnia. Such effects, while classified as physical side effects, can often be associated with a subsequent change in a person's general demeanor or state of mind.

Q: Do people typically experience withdrawal symptoms if Afonilum is stopped?

Official clinical discussions suggest that there is no specific rebound or withdrawal syndrome documented for this medicine when it is discontinued. The main issue noted is the possibility that the patient's underlying respiratory symptoms may return or worsen once the medicine's therapeutic effect wears off.

Q: What percentage of people in studies reported a side effect with Afonilum?

Historical regulatory evaluations note that when dosing is managed according to current guidelines, fewer than 3 percent of children and less than 10 percent of adults experienced minor side effects. This frequency is understood to increase significantly if the concentration of the medicine in the blood rises above the therapeutic range.

Afonilum (Choline Theophyllinate) must be stored and handled according to the regulatory requirements defined on the product label to ensure its stability.

Storage Requirement	Official Regulatory Statement
Temperature and Environment	Store at controlled room temperature and protect from moisture and excessive heat.
Container Integrity	Keep the medicine in its original container and ensure the container is tightly closed when not in use.
Child Safety	Keep out of the sight and reach of children (mandatory for all medicines).

The medicine remains stable only until the expiry date listed on the packaging, provided the labeled storage conditions are met. Disposal of any unused or expired Afonilum must adhere strictly to local and national regulations for pharmaceutical waste. The product should not be flushed down the toilet or placed in household trash unless explicitly directed by the official drug labeling or a government-authorized take-back program.